Patient perception and approval of faecal microbiota transplantation (FMT) as an alternative treatment option for obesity

被引:13
|
作者
Gundling, F. [1 ]
Roggenbrod, S. [1 ]
Schleifer, S. [1 ]
Sohn, M. [2 ]
Schepp, W. [1 ]
机构
[1] Tech Univ Munich, Dept Gastroenterol Hepatol & Gastrointestinal Onc, Acad Teaching Hosp Bogenhausen, Englschalkinger St 77, D-81925 Munich, Germany
[2] Univ Munich, Dept Visceral Surg, Acad Teaching Hosp Bogenhausen, Munich, Germany
来源
OBESITY SCIENCE & PRACTICE | 2019年 / 5卷 / 01期
关键词
Fecal microbiota transfer; microbiota obesity; weight loss endoscopy trial (WET); ULCERATIVE-COLITIS; GUT MICROBIOTA; ENERGY-BALANCE; WEIGHT-LOSS; MECHANISMS; DIET;
D O I
10.1002/osp4.302
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction Fecal microbiota transplantation (FMT) represents a treatment option for some diseases, e.g. recurring Clostridium difficile-associated colitis. However, there is also evidence that FMT can be effective in treating obesity. This pilot study established the approval and willingness of obese patients to undergo FMT. Methods We conducted a survey of adults with obesity using a questionnaire containing 21 both multiple choice and open questions was dispatched to a cohort of 101 persons with obesity. It included questions aiming at the process of FMT itself, donors as well as possible concerns. Additionally aspects of social background and disease activity were dealt with. Results The response rate amounted to 30.1% (n = 31). In our population, mean BMI was 40.5 kg/m(2) while the vast majority already tried out treatment modalities to lose weight before. 25.8% of persons with obesity were aware of FMT. 62.1% were willing to undergo FMT if the donor was healthy and anonymous while only 6.9% clearly refused this option. Sixty preferred an anonymous donor or a person proposed by their doctor while colonoscopy was the preferred application by 76.7%. The absence of risks of the procedure (47.8%) formed the principal motivation while reduction of medication was considered as least important reason (in 26.1). Insufficient testing of the faeces concerning infections raised the most concerns (in 61.6%). Conclusion For the majority of the persons with obesity surveyed FMT represents a treatment option. Approximately two thirds of the questionees would consider FMT as an alternative treatment option, even in spite of a satisfactory disease response to current standard therapies. Unsurprisingly there are concerns in regard to the transmission of possible infectious agents as well as to the hygieneic implementation of FMT itself.
引用
收藏
页码:68 / 74
页数:7
相关论文
共 50 条
  • [31] Clinical and immunologic effects of faecal microbiota transplantation in a patient with collagenous colitis
    Gunaltay, Sezin
    Rademacher, Lech
    Hornquist, Elisabeth Hultgren
    Bohr, Johan
    WORLD JOURNAL OF GASTROENTEROLOGY, 2017, 23 (07) : 1319 - 1324
  • [32] A patient with severe Crohn's colitis responds to Faecal Microbiota Transplantation
    Gordon, Hannah
    Harbord, Marcus
    JOURNAL OF CROHNS & COLITIS, 2014, 8 (03): : 256 - 257
  • [33] Faecal microbiota transplantation as a non-standard therapy for the treatment of Clostridioides difficile in an ulcerative colitis patient
    Pendrasik, Karolina
    Gocel, Oliwia
    Winter, Katarzyna
    Malecka-Wojciesko, Ewa
    GASTROENTEROLOGY REVIEW-PRZEGLAD GASTROENTEROLOGICZNY, 2022, 17 (04): : 338 - 341
  • [34] Fecal Microbiota Transplantation (FMT) for Treatment of Clostridium difficile Infection (CDI) in Immunocompromised Patients
    Ihunnah, Chioma
    Khoruts, Alexander
    Fischer, Monika
    Afzali, Anita
    Aroniadis, Olga
    Barto, Amy
    Borody, Thomas
    Brandt, Lawrence
    Giovanelli, Andrea
    Gordon, Shelley
    Hohmann, Elizabeth
    Kao, Dina
    Kao, John
    McQuillen, Daniel
    Mellow, Mark
    Rank, Kevin
    Ray, Arnab
    Schwartz, Margot
    Singh, Namita
    Stollman, Neil
    Surawicz, Christina
    Suskind, David
    Vindigni, Stephen
    Youngster, Ilan
    Kelly, Colleen
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2013, 108 : S179 - S180
  • [35] Is faecal microbiota transplantation an option to eradicate highly drug-resistant enteric bacteria carriage?
    Davido, B.
    Batista, R.
    Michelon, H.
    Lepainteur, M.
    Bouchand, F.
    Lepeule, R.
    Salomon, J.
    Vittecoq, D.
    Duran, C.
    Escaut, L.
    Sobhani, I.
    Paul, M.
    Lawrence, C.
    Perronne, C.
    Chast, F.
    Dinh, A.
    JOURNAL OF HOSPITAL INFECTION, 2017, 95 (04) : 433 - 437
  • [36] Successful treatment of chronic Pouchitis utilizing fecal microbiota transplantation (FMT): a case report
    Fang, Shuyang
    Kraft, Colleen S.
    Dhere, Tanvi
    Srinivasan, Jahnavi
    Begley, Beth
    Weinstein, David
    Shaffer, Virginia O.
    INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2016, 31 (05) : 1093 - 1094
  • [37] Fecal Microbiota Transplantation (FMT) in the Treatment of Inflammatory Bowel Disease (IBD): A Case Report
    Kao, Dina
    Madsen, Karen
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2013, 108 : S415 - S416
  • [38] Is fecal microbiota transplantation (FMT) an effective treatment for patients with functional gastrointestinal disorders (FGID)?
    Pinn, D. M.
    Aroniadis, O. C.
    Brandt, L. J.
    NEUROGASTROENTEROLOGY AND MOTILITY, 2015, 27 (01): : 19 - 29
  • [39] Successful treatment of chronic Pouchitis utilizing fecal microbiota transplantation (FMT): a case report
    Shuyang Fang
    Colleen S. Kraft
    Tanvi Dhere
    Jahnavi Srinivasan
    Beth Begley
    David Weinstein
    Virginia O. Shaffer
    International Journal of Colorectal Disease, 2016, 31 : 1093 - 1094
  • [40] Faecal Microbiota Therapy as a Treatment Option for a Clostridium difficile-induced toxic Megacolon
    Konturek, Peter
    Dieterich, Walburga
    Hess, Thomas
    Neurath, Markus F.
    Zopf, Yurdaguel
    INTERNIST, 2018, 59 : S28 - S28